Stability of first trimester placental growth factor in serum and whole blood

被引:25
作者
Cowans, N. J. [1 ]
Alfthan, H. [2 ]
Stenman, U. H. [2 ]
Spencer, K. [1 ]
机构
[1] King George Hosp, Dept Clin Biochem, Prenatal Screening Unit, Goodmayes IG3 8YB, Essex, England
[2] Univ Helsinki, Cent Hosp, HUSLAB, Biomedicum, FIN-00014 Helsinki, Finland
关键词
PLGF; stability; screening; pre-eclampsia; ANGIOGENIC FACTORS; CRYSTAL-STRUCTURE; PREECLAMPSIA; PREDICTION; COMPLEX; PLASMA;
D O I
10.1002/pd.2894
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Placental growth factor (PlGF) is a proposed first-trimester screening marker for pre-eclampsia. This study investigates the stability of PlGF in serum and whole blood at typical routine storage temperatures. Methods Serum pools were stored at refrigerator temperature, room temperature or 30 degrees C for up to 30 days, or exposed to up to six freeze-thaw cycles. Whole blood was stored at room temperature or 30 degrees C for up to 6 days. PlGF was quantified using a DELFIA Xpress analyser. Results Placental growth factor levels increased over time, seemingly because of the dissociation of PlGF bound to a soluble binding protein, sFlt-1. Increase was slow in serum at refrigerator temperature, remaining stable (less than 10% change from start point) for at least 30 days. At room temperature PlGF was stable for 3.3 days and at 30 degrees C for 1 day. Serum PlGF remained stable for at least six freeze-thaw cycles. In whole blood, instability was worse, being stable for only 19.4 h at room temperature and just 3.3 h at 30 degrees C. Conclusion Routine screening of sample handling requires careful monitoring. However, no extra precautions need to be taken when PlGF is used for pre-eclampsia screening run alongside existing first trimester aneuploidy screening programs that include hCG. Copyright c 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:1193 / 1197
页数:5
相关论文
共 20 条
  • [1] Global burden of maternal death and disability
    AbouZahr, C
    [J]. BRITISH MEDICAL BULLETIN, 2003, 67 : 1 - 11
  • [2] Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia
    Akolekar, R.
    Zaragoza, E.
    Poon, L. C. Y.
    Pepes, S.
    Nicolaides, K. H.
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 32 (06) : 732 - 739
  • [3] ANDERSON G, 1991, CLIN CHEM, V37, P398
  • [4] Bdolah Y, 2005, CROAT MED J, V46, P728
  • [5] Brosens I A, 1972, Obstet Gynecol Annu, V1, P177
  • [6] Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy A Meta-Analysis
    Bujold, Emmanuel
    Roberge, Stephanie
    Lacasse, Yves
    Bureau, Marc
    Audibert, Francois
    Marcoux, Sylvie
    Forest, Jean-Claude
    Giguere, Yves
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 116 (02) : 402 - 414
  • [7] Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing
    Cao, YH
    Ji, WDR
    Qi, P
    Rosin, A
    Cao, YM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) : 493 - 498
  • [8] The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1
    Christinger, HW
    Fuh, G
    de Vos, AM
    Wiesmann, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) : 10382 - 10388
  • [9] PAPP-A and free β-hCG stability in first trimester serum using PerkinElmer AutoDELFIA® and DELFIA® Xpress systems
    Cowans, Nicholas J.
    Stamatopoulou, Anastasia
    Hellstrom, Johanna
    Makela, Minna-Maarit
    Spencer, Kevin
    [J]. PRENATAL DIAGNOSIS, 2010, 30 (02) : 127 - 132
  • [10] Screening for Pre-eclampsia-Lessons from Aneuploidy Screening
    Cuckle, H. S.
    [J]. PLACENTA, 2011, 32 : S42 - S48